<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02377323</url>
  </required_header>
  <id_info>
    <org_study_id>NE156</org_study_id>
    <nct_id>NCT02377323</nct_id>
  </id_info>
  <brief_title>Real-Life Outcomes of Multiple Sclerosis Treatment With Rebif</brief_title>
  <acronym>RLO</acronym>
  <official_title>Real-Life Outcomes of Multiple Sclerosis Treatment With Rebif on Employment Status, Quality of Life and Cognition: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EMD Serono Canada Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Rebif has an impact on employment status,
      quality of life and cognition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With this study the investigator plans to evaluate the impact of Rebif on the Real-Life
      Outcomes (RLO) of Multiple Sclerosis (MS) patients followed at the Clinic within the last two
      years, and with a follow-up of up to 18 years.

      The investigator will evaluate the employment outcomes with a questionnaire designed to
      document eventual changes in the employment status and other variables in the work conditions
      of the study participants.

      Furthermore, to evaluate the quality of life (QoL),eligible patients will be asked to
      complete the Multiple Sclerosis Quality of Life (MSQOL)-54 Instrument, contains 52 items
      distributed into 12 scales, and two single items. This MS-specific QoL assessment tool uses
      the Short Form Health Survey (SF-36) as its generic core measure and includes 18 additional
      items under the following categories: health distress, sexual function, satisfaction with
      sexual function (one item), overall quality of life, cognitive function, energy, pain, and
      social function.

      A sub-group of patients will be selected to come to the clinic to undergo the cognitive
      portion of the study, using the well-known and validated battery of tests named Minimal
      Assessment of Cognitive Function in MS (MACFIMS battery).

      Socio-demographic data on education level, marital and family life will also be collected.
      All questionnaires (including the MSQoL-54) will be available by means of an online survey.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Employment status</measure>
    <time_frame>baseline</time_frame>
    <description>The primary endpoint is the proportion of patients in each group belonging in the employment categories listed below:
Never worked
Work status unchanged
Work status changed: Not due to MS / Due to MS
Sub-groups:
Full employment with accommodations
Part-time employment
Complete invalidity
Patient retired</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Baseline</time_frame>
    <description>The MSQoL-54 scores of the Rebif treated patient group compared to the never treated patient group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>Baseline</time_frame>
    <description>The comparison of the score of each patient group using the MACFIMS cognitive function tests.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinical variables - Composite measure</measure>
    <time_frame>baseline</time_frame>
    <description>The comparison of the clinical variables such as the Kurtzke Expanded Disability Status Scale (EDSS), relapse-rate, MS course and, when available, magnetic resonance imaging (MRI) of each patient group.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">296</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Treatment with Rebif</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients treated with Rebif only, for at least two years, and for up to 18 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Never treated</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients never treated with a disease-modifying drug (DMD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MACFIMS</intervention_name>
    <description>Cognitive evaluation of 50 participants</description>
    <arm_group_label>Treatment with Rebif</arm_group_label>
    <arm_group_label>Never treated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MSQoL-54</intervention_name>
    <description>Quality of life questionnaires</description>
    <arm_group_label>Treatment with Rebif</arm_group_label>
    <arm_group_label>Never treated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with CIS or definite MS (RRMS or SPMS);

          -  Patients seen at our Clinic within the last 2 years;

          -  Patients untreated, or treated with either low dose or high dose Rebif for at least
             two years;

          -  Patients between 18 to 60 years old at time of treatment initiation;

          -  EDSS ≤ 5.5 at treatment initiation;

          -  Patients able to read and write in French.

        Exclusion Criteria:

          -  Patients diagnosed with primary progressive MS;

          -  Patients treated with other DMD, other than Rebif;

          -  Co-existence of other diseases that could influence outcomes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Duquette, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHUM</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Zipoli V, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Lepore V, Livrea P, Comi G, Amato MP; Italian Multiple Sclerosis Database Network (MSDN) Group. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol. 2009 Oct;66(4):513-20. doi: 10.1002/ana.21757.</citation>
    <PMID>19847899</PMID>
  </reference>
  <reference>
    <citation>Glanz BI, Dégano IR, Rintell DJ, Chitnis T, Weiner HL, Healy BC. Work productivity in relapsing multiple sclerosis: associations with disability, depression, fatigue, anxiety, cognition, and health-related quality of life. Value Health. 2012 Dec;15(8):1029-35. doi: 10.1016/j.jval.2012.07.010. Epub 2012 Oct 25.</citation>
    <PMID>23244804</PMID>
  </reference>
  <reference>
    <citation>Krokavcova M, Nagyova I, Van Dijk JP, Rosenberger J, Gavelova M, Middel B, Szilasiova J, Gdovinova Z, Groothoff JW. Self-rated health and employment status in patients with multiple sclerosis. Disabil Rehabil. 2010;32(21):1742-8. doi: 10.3109/09638281003734334.</citation>
    <PMID>20350069</PMID>
  </reference>
  <reference>
    <citation>Roessler RT, Rumrill PD Jr. Multiple sclerosis and employment barriers: a systemic perspective on diagnosis and intervention. Work. 2003;21(1):17-23.</citation>
    <PMID>12897387</PMID>
  </reference>
  <reference>
    <citation>Beatty WW, Hames KA, Blanco CR, et al. Demographic, clinical and cognitive characteristics of multiple sclerosis patients who continue to work. J Neurol Rehab 1995; 9:167-73.</citation>
  </reference>
  <reference>
    <citation>Simmons RD, Tribe KL, McDonald EA. Living with multiple sclerosis: longitudinal changes in employment and the importance of symptom management. J Neurol. 2010 Jun;257(6):926-36. doi: 10.1007/s00415-009-5441-7. Epub 2010 Jan 19.</citation>
    <PMID>20084515</PMID>
  </reference>
  <reference>
    <citation>Larocca N, Kalb R, Scheinberg L, Kendall P. Factors associated with unemployment of patients with multiple sclerosis. J Chronic Dis. 1985;38(2):203-10.</citation>
    <PMID>3156140</PMID>
  </reference>
  <reference>
    <citation>Smith MM, Arnett PA. Factors related to employment status changes in individuals with multiple sclerosis. Mult Scler. 2005 Oct;11(5):602-9.</citation>
    <PMID>16193900</PMID>
  </reference>
  <reference>
    <citation>Verdier-Taillefer MH, Sazdovitch V, Borgel F, Césaro P, Kurtz A, Millet MF, Roullet E, Marteau R. Occupational environment as risk factor for unemployment in multiple sclerosis. Acta Neurol Scand. 1995 Jul;92(1):59-62.</citation>
    <PMID>7572062</PMID>
  </reference>
  <reference>
    <citation>Glad SB, Nyland H, Aarseth JH, Riise T, Myhr KM. How long can you keep working with benign multiple sclerosis? J Neurol Neurosurg Psychiatry. 2011 Jan;82(1):78-82. doi: 10.1136/jnnp.2010.210732. Epub 2010 Aug 27.</citation>
    <PMID>20802029</PMID>
  </reference>
  <reference>
    <citation>Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology. 1991 May;41(5):692-6.</citation>
    <PMID>1823781</PMID>
  </reference>
  <reference>
    <citation>Benito-León J, Morales JM, Rivera-Navarro J, Mitchell A. A review about the impact of multiple sclerosis on health-related quality of life. Disabil Rehabil. 2003 Dec 2;25(23):1291-303. Review.</citation>
    <PMID>14617435</PMID>
  </reference>
  <reference>
    <citation>Rudick RA, Miller D, Clough JD, Gragg LA, Farmer RG. Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis. Arch Neurol. 1992 Dec;49(12):1237-42.</citation>
    <PMID>1449401</PMID>
  </reference>
  <reference>
    <citation>Kobelt G, Berg J, Lindgren P, Kerrigan J, Russell N, Nixon R. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Health Econ. 2006 Sep;7 Suppl 2:S96-104.</citation>
    <PMID>17310341</PMID>
  </reference>
  <reference>
    <citation>Solari A. Role of health-related quality of life measures in the routine care of people with multiple sclerosis. Health Qual Life Outcomes. 2005 Mar 18;3:16. Review.</citation>
    <PMID>15777478</PMID>
  </reference>
  <reference>
    <citation>Amato MP, Zipoli V, Portaccio E. Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies. J Neurol Sci. 2006 Jun 15;245(1-2):41-6. Epub 2006 Apr 27. Review.</citation>
    <PMID>16643953</PMID>
  </reference>
  <reference>
    <citation>Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology. 1991 May;41(5):685-91.</citation>
    <PMID>2027484</PMID>
  </reference>
  <reference>
    <citation>Amato MP, Ponziani G, Pracucci G, Bracco L, Siracusa G, Amaducci L. Cognitive impairment in early-onset multiple sclerosis. Pattern, predictors, and impact on everyday life in a 4-year follow-up. Arch Neurol. 1995 Feb;52(2):168-72.</citation>
    <PMID>7848126</PMID>
  </reference>
  <reference>
    <citation>Kujala P, Portin R, Ruutiainen J. The progress of cognitive decline in multiple sclerosis. A controlled 3-year follow-up. Brain. 1997 Feb;120 ( Pt 2):289-97.</citation>
    <PMID>9117376</PMID>
  </reference>
  <reference>
    <citation>Jennekens-Schinkel A, Laboyrie PM, Lanser JB, van der Velde EA. Cognition in patients with multiple sclerosis After four years. J Neurol Sci. 1990 Nov;99(2-3):229-47.</citation>
    <PMID>2086726</PMID>
  </reference>
  <reference>
    <citation>Amato MP, Ponziani G, Siracusa G, Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol. 2001 Oct;58(10):1602-6.</citation>
    <PMID>11594918</PMID>
  </reference>
  <reference>
    <citation>Benedict RH, Cookfair D, Gavett R, Gunther M, Munschauer F, Garg N, Weinstock-Guttman B. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc. 2006 Jul;12(4):549-58.</citation>
    <PMID>16981607</PMID>
  </reference>
  <reference>
    <citation>Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult Scler. 1999 Aug;5(4):251-9. Review.</citation>
    <PMID>10467384</PMID>
  </reference>
  <reference>
    <citation>Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Qual Life Res. 1995 Jun;4(3):187-206.</citation>
    <PMID>7613530</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2014</study_first_submitted>
  <study_first_submitted_qc>March 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</investigator_affiliation>
    <investigator_full_name>Pierre Duquette</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Patient-reported outcomes</keyword>
  <keyword>Employment status</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Cognition</keyword>
  <keyword>Rebif</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferon beta-1a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

